1. Hepatitis C virus (HCV) is the most common indication for living donor liver transplantation (LDLT).
2. Preliminary evidence suggests that HCV may occur earlier and may be more severe in LDLT recipients. However, current data is inconclusive relative to the impact of recurrent HCV on patient and graft survival in LDLT recipients.
3. Potential mechanisms for differences in severity of HCV in LDLT recipients are discussed.
4. LDLT remains a viable treatment option for selected patients with HCV.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.